title: Randomized clinical trials for colorectal cancer peritoneal surface malignancy.
abstract: Upwards of 40% of patient with colorectal cancer develop peritoneal carcinomatosis (CRCPC). Of the 2500 patients reported in the literature, 1000 underwent cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC), resulting in median survival of 22 to 63 months. However, level I data from prospective randomized trials are limited. Further trials are indicated to identify peritoneal carcinomatosis in at-risk patients early in the natural history of the disease and confirm the efficacy of multimodality therapy (CRS/HIPEC/systemic therapy) in those with CRCPC amenable to CRS in the modern era of novel targeted and cytotoxic systemic therapy.
authors.affiliation: Bon Secours Cancer Institute, Peritoneal Surface Malignancies Center of Excellence, Richmond, VA 23226, USA.
authors.forename: Itzhak
authors.initials: I
authors.lastname: Avital
authors.forename: Björn L D M
authors.initials: BL
authors.lastname: Brücher
authors.forename: Aviram
authors.initials: A
authors.lastname: Nissan
authors.forename: Alexander
authors.initials: A
authors.lastname: Stojadinovic
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002277:Carcinoma / Q000188:drug therapy / Q000473:pathology* / Q000601:surgery; D010478:Chemotherapy, Cancer, Regional Perfusion / Q000379:methods*; D015179:Colorectal Neoplasms / Q000188:drug therapy / Q000473:pathology* / Q000601:surgery; D018450:Disease Progression; D019317:Evidence-Based Medicine; D006801:Humans; D006979:Hyperthermia, Induced / Q000379:methods*; D007263:Infusions, Parenteral; D010534:Peritoneal Neoplasms / Q000188:drug therapy / Q000556:secondary* / Q000601:surgery; D016032:Randomized Controlled Trials as Topic
chemical_list: D000970:Antineoplastic Agents